Base de dados : MEDLINE
Pesquisa : D23.050.301 [Categoria DeCS]
Referências encontradas : 30460 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3046 ir para página                         

  1 / 30460 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384939
[Au] Autor:Xing P; Dong H; Liu Q; Zhao T; Yao F; Xu Y; Chen B; Zheng X; Wu Y; Jin F; Li J
[Ad] Endereço:Breast Division, the First Hospital of China Medical University, Shenyang, Liaoning, China.
[Ti] Título:Upregulation of transmembrane 4 L6 family member 1 predicts poor prognosis in invasive breast cancer: A STROBE-compliant article.
[So] Source:Medicine (Baltimore);96(52):e9476, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Transmembrane 4 L6 family member 1 (TM4SF1) belongs to the 4-transmembrane-domain family and functions as an oncogene in multiple human cancers. In this work, we aim to determine TM4SF1 expression and its prognostic impact on patients with invasive breast cancer.Overall, we enrolled 209 invasive breast cancer patients and immunohistochemically examined the expression of TM4SF1 in tumor specimens. The relationship between TM4SF1 expression and clinicopathological parameter and patient survival of breast cancer patients was analyzed.Among the 209 cases, 137 (65.6%) exhibited high expression of TM4SF1. High TM4SF1 expression was significantly associated with advanced histological grade and negative estrogen receptor and progesterone receptor status. Triple-negative breast cancer (TNBC) tumors were more likely to express high levels of TM4SF1 than non-TNBC cases. Patients with high tumoral expression of TM4SF1 had a significantly shorter disease-free survival (DFS; P = .00) and overall survival (OS; P = .01) than those with low expression of TM4SF1. When survival analysis was restricted to the 167 patients (79.9%) receiving adjuvant chemotherapy, TM4SF1 expression was also correlated with poorer DFS and OS (P = .00). In multiple Cox regression analysis TM4SF1 expression remained an independent prognostic indicator for OS and DFS.TM4SF1 is upregulated and serves as an independent poor prognostic indicator in invasive breast cancer.
[Mh] Termos MeSH primário: Antígenos de Superfície/biossíntese
Neoplasias da Mama/mortalidade
Neoplasias da Mama/patologia
Regulação Neoplásica da Expressão Gênica/fisiologia
Proteínas de Neoplasias/biossíntese
Regulação para Cima/fisiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Biomarcadores Tumorais
Feminino
Seres Humanos
Meia-Idade
Gradação de Tumores
Invasividade Neoplásica
Prognóstico
Receptor ErbB-2/metabolismo
Receptores Estrogênicos/metabolismo
Receptores de Progesterona/metabolismo
Análise de Sobrevida
Ativação Transcricional
Neoplasias de Mama Triplo Negativas/mortalidade
Neoplasias de Mama Triplo Negativas/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Surface); 0 (Biomarkers, Tumor); 0 (Neoplasm Proteins); 0 (Receptors, Estrogen); 0 (Receptors, Progesterone); 147016-68-0 (TM4SF1 protein, human); EC 2.7.10.1 (Receptor, ErbB-2)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009476


  2 / 30460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27777771
[Au] Autor:Hall M; Liu H; Malafa M; Centeno B; Hodul PJ; Pimiento J; Pilon-Thomas S; Sarnaik AA
[Ad] Endereço:Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL USA.
[Ti] Título:Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.
[So] Source:J Immunother Cancer;4:61, 2016.
[Is] ISSN:2051-1426
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We evaluated whether tumor infiltrating lymphocytes (TIL) could be expanded from surgically resected tumors from pancreatic cancer patients. METHODS: Tumors were resected from pancreatic cancer patients. Tumors were minced into fragments and cultured in media containing high dose interleukin-2 (IL-2) for up to 6 weeks. T cell phenotype, activation markers, and reactivity were measured. RESULTS: TIL expansion was measured in 19 patient samples. The majority of these TIL were CD4 T cells and were highly activated. Purified CD8 T cells produced IFN-γ in response to HLA-matched pancreatic tumor targets. PD-1 blockade and 4-1BB stimulation were demonstrated as effective strategies to improve effective TIL yield, including the production of tumor-reactive pancreatic TIL. CONCLUSIONS: TIL expanded from pancreatic tumors are functional and able to respond to pancreatic tumor associated antigens. PD-1 blockade, 41BB stimulation, and CD8 T cell enrichment are effective strategies to improve TIL yield and tumor reactivity. These results support the development of adoptive cell therapy strategies using TIL for the treatment of pancreatic cancer.
[Mh] Termos MeSH primário: Subpopulações de Linfócitos/imunologia
Linfócitos do Interstício Tumoral/imunologia
Neoplasias Pancreáticas/imunologia
[Mh] Termos MeSH secundário: Antígenos de Superfície/metabolismo
Antineoplásicos Imunológicos/farmacologia
Antineoplásicos Imunológicos/uso terapêutico
Biomarcadores
Técnicas de Cultura de Células
Citotoxicidade Imunológica
Antígenos HLA/imunologia
Seres Humanos
Imunomodulação/efeitos dos fármacos
Imunofenotipagem
Interleucina-2/farmacologia
Ativação Linfocitária
Contagem de Linfócitos
Subpopulações de Linfócitos/efeitos dos fármacos
Subpopulações de Linfócitos/metabolismo
Subpopulações de Linfócitos/patologia
Linfócitos do Interstício Tumoral/efeitos dos fármacos
Linfócitos do Interstício Tumoral/metabolismo
Linfócitos do Interstício Tumoral/patologia
Neoplasias Pancreáticas/tratamento farmacológico
Neoplasias Pancreáticas/patologia
Neoplasias Pancreáticas/cirurgia
Fenótipo
Receptor de Morte Celular Programada 1/antagonistas & inibidores
Especificidade do Receptor de Antígeno de Linfócitos T/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Surface); 0 (Antineoplastic Agents, Immunological); 0 (Biomarkers); 0 (HLA Antigens); 0 (Interleukin-2); 0 (Programmed Cell Death 1 Receptor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1186/s40425-016-0164-7


  3 / 30460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27777769
[Au] Autor:Stanton SE; Disis ML
[Ad] Endereço:Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, 850 Republican Street, 2nd Floor, Box 358050, Seattle, WA 98195-8050 USA.
[Ti] Título:Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
[So] Source:J Immunother Cancer;4:59, 2016.
[Is] ISSN:2051-1426
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple negative breast cancers (TN) are most likely to have tumors with >50 % lymphocytic infiltrate, termed lymphocyte predominant breast cancer, and derive the greatest survival benefit from each 10 % increase in TIL. The majority of HER2 breast cancers have similar level of immune infiltrate as TN breast cancer yet the presence of TILs has not shown the same survival benefit. For HER2 breast cancers, type 1 T-cells, either increased TBET tumor infiltration or increased type 1 HER2-specific CD4 T-cells in the peripheral blood, are associated with better outcomes. Hormone receptor positive HER2 negative tumors tend to have the least immune infiltrate yet are the only breast cancer subtype to show worse prognosis with increased FOXP3 regulatory T-cell infiltrate. Notably, all breast cancer subtypes have tumors with low, intermediate, or high TIL infiltrate. Tumors with high TILs may also have increased PD-L1 expression which might be the reason that TN breast cancer seems to demonstrate the most robust clinical response to immune checkpoint inhibitor therapy but further investigation is needed. Tumors with intermediate or low levels of pre-treatment immune infiltrate, on the other hand, may benefit from an intervention that may increase TIL, particularly type 1 T-cells. Examples of these interventions include specific types of cytotoxic chemotherapy, radiation, or vaccine therapy. Therefore, the systematic evaluation of TIL and specific populations of TIL may be able to both guide prognosis and the appropriate sequencing of therapies in breast cancer.
[Mh] Termos MeSH primário: Neoplasias da Mama/imunologia
Neoplasias da Mama/mortalidade
Subpopulações de Linfócitos/imunologia
Linfócitos do Interstício Tumoral/imunologia
[Mh] Termos MeSH secundário: Animais
Antígenos de Superfície/metabolismo
Antineoplásicos Imunológicos/farmacologia
Antineoplásicos Imunológicos/uso terapêutico
Biomarcadores
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/metabolismo
Citotoxicidade Imunológica
Feminino
Seres Humanos
Imunomodulação/efeitos dos fármacos
Contagem de Linfócitos
Subpopulações de Linfócitos/metabolismo
Subpopulações de Linfócitos/patologia
Linfócitos do Interstício Tumoral/metabolismo
Linfócitos do Interstício Tumoral/patologia
Terapia de Alvo Molecular
Prognóstico
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antigens, Surface); 0 (Antineoplastic Agents, Immunological); 0 (Biomarkers)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  4 / 30460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28747524
[Au] Autor:Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
[Ad] Endereço:Department of Diagnostic Imaging, St. Vincent's Public Hospital, Sydney, Australia emmetthruby@gmail.com.
[Ti] Título:Treatment Outcomes from Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.
[So] Source:J Nucl Med;58(12):1972-1976, 2017 Dec.
[Is] ISSN:1535-5667
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Ga-PSMA (prostate-specific membrane antigen) PET/CT is increasingly used in men with prostate-specific antigen (PSA) failure after radical prostatectomy (RP) to triage those who will benefit from salvage radiation treatment (SRT). This study examines the value of PSMA-informed SRT in improving treatment outcomes in the context of biochemical failure after RP. We analyzed men with rising PSA after RP with PSA readings between 0.05 and 1.0 ng/mL, considered eligible for SRT at the time of PSMA. For each patient, clinical and pathologic features as well as scan results, including site of PSMA-positive disease, number of lesions, and a certainty score, were documented. Subsequent management, including SRT, and most recent PSA were recorded using medical records. Treatment response was defined as both PSA ≤ 0.1 ng/mL and >50% reduction in PSA. Multivariate logistic regression analysis was performed for association of clinical variables and treatment response to SRT. One hundred sixty-four men were included. PSMA was positive in 62% ( = 102/164): 38 of 102 in the prostatic fossa, 41 of 102 in pelvic nodes, and 23 of 102 distantly. Twenty-four patients received androgen-deprivation therapy (ADT) and were excluded for outcomes analysis. In total, 99 of 146 received SRT with a median follow-up after radiation treatment of 10.5 mo (interquartile range, 6-14 mo). Overall treatment response after SRT was 72% ( = 71/99). Forty-five percent ( = 27/60) of patients with a negative PSMA underwent SRT whereas 55% (33/60) did not. In men with a negative PSMA who received SRT, 85% ( = 23/27) demonstrated a treatment response, compared with a further PSA increase in 65% (22/34) in those not treated. In 36 of 99 patients with disease confined to the prostate fossa on PSMA, 81% ( = 29/36) responded to SRT. In total, 26 of 99 men had nodal disease on PSMA, of whom 61% ( = 16/26) had treatment response after SRT. On multivariate logistic regression analysis, PSMA and serum PSA significantly correlated with treatment response, whereas pT stage, Gleason score, and surgical margin status did not. PSMA PET is independently predictive of treatment response to SRT and stratifies men into a high treatment response to SRT (negative or fossa-confined PSMA) versus men with poor response to SRT (nodes or distant-disease PSMA). In particular, a negative PSMA PET result predicts a high response to salvage fossa radiotherapy.
[Mh] Termos MeSH primário: Recidiva Local de Neoplasia/diagnóstico por imagem
Recidiva Local de Neoplasia/radioterapia
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/métodos
Prostatectomia
Neoplasias da Próstata/diagnóstico por imagem
Neoplasias da Próstata/radioterapia
[Mh] Termos MeSH secundário: Idoso
Antígenos de Superfície
Terapia Combinada
Seguimentos
Glutamato Carboxipeptidase II
Seres Humanos
Masculino
Meia-Idade
Recidiva Local de Neoplasia/patologia
Compostos Organometálicos
Administração dos Cuidados ao Paciente
Prognóstico
Antígeno Prostático Específico/análise
Neoplasias da Próstata/patologia
Compostos Radiofarmacêuticos
Terapia de Salvação
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Surface); 0 (Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))); 0 (Organometallic Compounds); 0 (Radiopharmaceuticals); EC 3.4.17.21 (Glutamate Carboxypeptidase II); EC 3.4.17.21 (glutamate carboxypeptidase II, human); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.2967/jnumed.117.196683


  5 / 30460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461659
[Au] Autor:Kohl TO; Ascoli CA
[Ti] Título:Direct and Indirect Cell-Based Enzyme-Linked Immunosorbent Assay.
[So] Source:Cold Spring Harb Protoc;2017(5):pdb.prot093732, 2017 May 01.
[Is] ISSN:1559-6095
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The direct cell-based enzyme-linked immunosorbent assay (ELISA) has developed into a popular alternative immunoassay for the rapid detection of expressed cell-surface antigens or receptors. It is used to determine cell surface antigen expression profiles using existing reporter-labeled antibodies. The target specificity of newly developed antibodies can be determined by the indirect approach, which screens hybridoma supernatants for antibody reactivity against the target antigen of interest. The cell-based ELISA acts as a surrogate for the identification of immunohistochemistry-reactive (IHC) antibodies and aids in hybridoma-derived antibody identification, which is used for further ELISA development. Briefly, cells are adsorbed onto the microtiter plate surface and then fixed. Next, either hybridoma supernatant or reporter-labeled antibody is added and allowed to bind, followed by a washing step to remove unbound antibodies. For the indirect approach-during the screening of hybridoma supernatant-a reporter-labeled species-specific secondary antibody is added. For either approach, the next step is the addition of substrate. Substrate hydrolysis is proportional to the level of cell-surface antigen expression and can be measured using a microplate reader. Cell-based ELISAs have detection sensitivities comparable to quantitative analyses by flow cytometry and can be developed in multiplex format using different reporters for the analysis of cell populations.
[Mh] Termos MeSH primário: Antígenos de Superfície/análise
Ensaio de Imunoadsorção Enzimática/métodos
Receptores de Superfície Celular/análise
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/análise
Citometria de Fluxo
Hibridomas/imunologia
Imuno-Histoquímica
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antigens, Surface); 0 (Receptors, Cell Surface)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1101/pdb.prot093732


  6 / 30460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29284249
[Au] Autor:Schreterova E; Bhide M; Potocnakova L; Borszekova Pulzova L
[Ad] Endereço:Laboratory of Biomedical Microbiology and Immunology, Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy, 041 81 Kosice, Slovakia. eva.kendrovska@gmail.com.
[Ti] Título:Design, construction and evaluation of multi-epitope antigens for diagnosis of Lyme disease.
[So] Source:Ann Agric Environ Med;24(4):696-701, 2017 Dec 23.
[Is] ISSN:1898-2263
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Introduction and objective. Lyme disease (LD) is the most common vector-borne disease in the temperate zone of the Northern Hemisphere. Diagnosis of LD is mainly based on clinical symptoms supported with serology (detection of anti-Borrelia antibodies) and is often misdiagnosed in areas of endemicity. MATERIAL AND METHODS: In this study, the chimeric proteins (A/C-2, A/C-4 and A/C-7.1) consisting of B-cell epitopes of outer surface proteins OspA and OspC from Borrelia genospecies prevalent in Eastern Slovakia, were designed, over-expressed in E. coli, and used to detect specific anti-Borrelia antibodies in serologically characterized sera from patients with Lyme-like symptoms to evaluate their diagnostic potential. RESULTS: Results showed that chimeras vary in their immuno-reactivity when tested with human sera. Compared with the results obtained from a two-tier test, the application of recombinant multi-epitope chimeric proteins as diagnosis antigens, produced fair agreement in the case of A/C-2 (0.20<κ<0.40) and good agreement (0.60<κ<0.80) when A/C-7.1 was used as capture antigen. Chimera A/C-4 were excluded from further study due to loss of reactivity with OspA-specific antibodies. CONCLUSIONS: The combination of specific B-cell epitopes from OspA and OspC proteins may improve the diagnostic accuracy of serologic assays, but further studies are required to address this hypothesis.
[Mh] Termos MeSH primário: Borrelia burgdorferi/isolamento & purificação
Ensaio de Imunoadsorção Enzimática/métodos
Epitopos de Linfócito B/análise
Doença de Lyme/diagnóstico
[Mh] Termos MeSH secundário: Anticorpos Antibacterianos/análise
Anticorpos Antibacterianos/imunologia
Antígenos de Superfície/análise
Antígenos de Superfície/genética
Antígenos de Superfície/imunologia
Proteínas da Membrana Bacteriana Externa/análise
Proteínas da Membrana Bacteriana Externa/genética
Proteínas da Membrana Bacteriana Externa/imunologia
Vacinas Bacterianas/análise
Vacinas Bacterianas/genética
Vacinas Bacterianas/imunologia
Borrelia burgdorferi/genética
Borrelia burgdorferi/imunologia
Epitopos de Linfócito B/imunologia
Seres Humanos
Lipoproteínas/análise
Lipoproteínas/genética
Lipoproteínas/imunologia
Doença de Lyme/imunologia
Doença de Lyme/microbiologia
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Antigens, Surface); 0 (Bacterial Outer Membrane Proteins); 0 (Bacterial Vaccines); 0 (Epitopes, B-Lymphocyte); 0 (Lipoproteins); 0 (OspA protein)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171230
[St] Status:MEDLINE


  7 / 30460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277757
[Au] Autor:Michalska M; Schultze-Seemann S; Kuckuck I; Wolf P
[Ad] Endereço:Department of Urology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
[Ti] Título: Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer.
[So] Source:Anticancer Res;38(1):61-69, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We generated humanized/de-immunized immunotoxins targeting the prostate-specific membrane antigen (PSMA) and tested their cytotoxic activity against prostate cancer cells in vitro. MATERIALS AND METHODS: The humanized/de-immunized version of our murine anti-PSMA single-chain antibody fragment (scFv) D7, termed hD7-1(VL-VH), was ligated to the 40-kDa toxin domain of Pseudomonas aeruginosa exotoxin A (PE40), and to the deimmunized 24-kDa toxin domains PE24 or PE24mut. The immunotoxins designated as hD7-1(VL-VH)-PE40, hD7-1(VL-VH)-PE24 and hD7-1(VL-VH)-PE24mut were bacterially expressed and purified by affinity chromatography. Binding and cytotoxicity were examined by flow cytometry and viability assay, respectively. RESULTS: All immunotoxins revealed strong binding to prostate cancer cells expressing PSMA and specific cytotoxicity, with half-maximal inhibitory concentration values in the picomolar range. CONCLUSION: We successfully created powerful anti-PSMA immunotoxins with reduced immunogenicity for further clinical development and application against advanced prostate cancer.
[Mh] Termos MeSH primário: Antígenos de Superfície/imunologia
Glutamato Carboxipeptidase II/imunologia
Imunotoxinas/farmacologia
Neoplasias da Próstata/imunologia
[Mh] Termos MeSH secundário: ADP Ribose Transferases/genética
ADP Ribose Transferases/imunologia
Animais
Toxinas Bacterianas/genética
Toxinas Bacterianas/imunologia
Linhagem Celular Tumoral
Escherichia coli/genética
Exotoxinas/genética
Exotoxinas/imunologia
Seres Humanos
Masculino
Camundongos
Neoplasias da Próstata/tratamento farmacológico
Fatores de Virulência/genética
Fatores de Virulência/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Surface); 0 (Bacterial Toxins); 0 (Exotoxins); 0 (Immunotoxins); 0 (Virulence Factors); EC 2.4.2.- (ADP Ribose Transferases); EC 2.4.2.31 (toxA protein, Pseudomonas aeruginosa); EC 3.4.17.21 (Glutamate Carboxypeptidase II); EC 3.4.17.21 (glutamate carboxypeptidase II, human)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  8 / 30460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29190736
[Au] Autor:Bommana S; Walker E; Desclozeaux M; Timms P; Polkinghorne A
[Ad] Endereço:Centre for Animal Health Innovation, University of the Sunshine Coast, Sippy Downs, Australia.
[Ti] Título:Humoral immune response against two surface antigens of Chlamydia pecorum in vaccinated and naturally infected sheep.
[So] Source:PLoS One;12(11):e0188370, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Chlamydia pecorum is a globally recognised livestock pathogen due to the significant clinical and economic impact it poses to livestock producers. Routine serological diagnosis is through a complement fixation test (CFT), which is often criticised for cross-reactivity, poor sensitivity and specificity. Although serology remains the preferred method in veterinary diagnostic laboratories, serological assays based on surface antigens of C. pecorum have not been established until now. In this study, we evaluated the use of two chlamydial recombinant protein antigens (PmpG and MOMP-G) by a direct IgG ELISA method for detection of ovine anti-chlamydial antibodies. Using the Pepscan method we then identified B cell epitopes across PmpG and MOMP-G proteins, in lambs with (a) naturally occurring asymptomatic C. pecorum infections (b) C. pecorum-associated polyarthritis and (c) recombinant PmpG and MOMP-G vaccine. Plasma IgG antibodies to PmpG in natural infection of lambs were detected earlier in infection than CFT and served as an acute phase marker. Antibodies to MOMP-G IgG were significantly heightened in lambs with C. pecorum-associated polyarthritis. PmpG and MOMP-G specific B-cell epitope mapping revealed epitope responses in immunised lambs cluster with some of the epitope responses in naturally infected lambs. B-cell epitope mapping further revealed that lambs with polyarthritis recognised several unique PmpG (50% frequency, peptide 8, 25, 40, 41 and 50) and MOMP (50% frequency, peptide 50) epitopes in comparison to asymptomatic infections. The findings of this study will have implications towards improved serodiagnosis of C. pecorum infections in livestock and inform the downstream development of alternative peptide-based antigens for future C. pecorum vaccine studies.
[Mh] Termos MeSH primário: Anticorpos Antibacterianos/biossíntese
Antígenos de Superfície/imunologia
Vacinas Bacterianas/administração & dosagem
Infecções por Chlamydia/veterinária
Chlamydia/imunologia
Doenças dos Ovinos/diagnóstico
[Mh] Termos MeSH secundário: Animais
Vacinas Bacterianas/imunologia
Infecções por Chlamydia/imunologia
Infecções por Chlamydia/microbiologia
Ensaio de Imunoadsorção Enzimática
Mapeamento de Epitopos
Ovinos
Doenças dos Ovinos/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Antigens, Surface); 0 (Bacterial Vaccines)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188370


  9 / 30460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29107272
[Au] Autor:Chaloupka M; Herlemann A; D'Anastasi M; Cyran CC; Ilhan H; Gratzke C; Stief CG
[Ad] Endereço:Department of Urology, Ludwig-Maximilians-University Munich, Marchioninistraße 15, Munich 81377, Germany. Electronic address: Michael.chaloupka@med.uni-muenchen.de.
[Ti] Título:Gallium-Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary and Secondary Staging in Prostate Cancer.
[So] Source:Urol Clin North Am;44(4):557-563, 2017 Nov.
[Is] ISSN:1558-318X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Prostate-specific membrane antigen (PSMA) PET has been recently introduced for the diagnosis of patients with metastatic prostate cancer (PCa). Until today, staging of patients with PCa relied mostly on morphologic features, such as size or shape, resulting in low detection rates in disease recurrence. PSMA PET imaging provides molecular information and, in combination with conventional imaging, offers improved sensitivity and specificity. This review discusses the benefits and limitations of PSMA imaging in the setting of primary staging and detection of recurrent disease in comparison with standard-of-care imaging techniques.
[Mh] Termos MeSH primário: Antígenos de Superfície/farmacologia
Glutamato Carboxipeptidase II/farmacologia
Estadiamento de Neoplasias/métodos
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/métodos
Neoplasias da Próstata/diagnóstico
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Período Pré-Operatório
Compostos Radiofarmacêuticos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antigens, Surface); 0 (Radiopharmaceuticals); EC 3.4.17.21 (Glutamate Carboxypeptidase II); EC 3.4.17.21 (glutamate carboxypeptidase II, human)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171107
[St] Status:MEDLINE


  10 / 30460 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28923329
[Au] Autor:Jia M; Yao H; Chen C; Wang Y; Wang H; Cui T; Zhu J
[Ad] Endereço:Laboratory of Clinical Immunology, Wuhan No.1 Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, PR China.
[Ti] Título:Prognostic Correlation Between MFG-E8 Expression Level and Colorectal Cancer.
[So] Source:Arch Med Res;48(3):270-275, 2017 Apr.
[Is] ISSN:1873-5487
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIMS: Colorectal cancer (CRC) is one of the leading causes of cancer-related death all over the world. Milk fat globule-epidermal growth factor (EGF)-factor VIII (MFG-E8) was found to be highly expressed in a variety of cancers. However its role in CRC is unclear. This study investigates the expression of MFG-E8 in CRC tissues and the correlation with clinicopathological features and prognosis in CRC patients. METHODS: The expression of MFG-E8 proteins was detected by immunohistochemical staining in 90 samples of CRC. The localization of MFG-E8 in colorectal tumor was examined by immunofluorescence staining. The correlation between MFG-E8 protein expression and the clinical pathological features of CRC were evaluated by χ test and Fisher's exact test. The survival rates were analyzed by the Kaplan-Meier method, and the relationship between prognostic factors and patient survival was analyzed by the Cox proportional hazard models. RESULTS: Our results showed that MFG-E8 expression increased significantly in colorectal cancer compared with normal mucosa tissues (p <0.001). We further validated MFG-E8 overexpression in 6 pairs of fresh tumor and adjacent normal mucosa tissues from colorectal cancer patients by Western blot (p <0.05). Immunofluorescence staining showed that MFG-E8 accumulated in close proximity to endothelial cells in human colorectal tumor tissue. In addition, high MFG-E8 protein expression was correlated with lymph node metastasis and some pathological classifications (p <0.05). Furthermore, patients with high protein level of MFG-E8 showed shortened overall survivals (p <0.05). CONCLUSION: Our results showed that MFG-E8 could be a potential novel prognostic marker for CRC and overexpression of MFG-E8 might be involved in lymph node metastasis and angiogenesis of CRC.
[Mh] Termos MeSH primário: Antígenos de Superfície/metabolismo
Neoplasias Colorretais/metabolismo
Proteínas do Leite/metabolismo
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/metabolismo
Neoplasias Colorretais/diagnóstico
Neoplasias Colorretais/patologia
Seres Humanos
Metástase Linfática
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Surface); 0 (Biomarkers, Tumor); 0 (MFGE8 protein, human); 0 (Milk Proteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170920
[St] Status:MEDLINE



página 1 de 3046 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde